Galera Labs, LLC

Millennium Pharmaceuticals Limited

Demegen, Inc.

David M Rothstein

Chris Murphy

Glenn Kazo

Vivien Wong

Phillip M Friden

Zhi-Dong Jiang

Peter Spacciapoli

Nagraj Mani

Vivian Wong

Glen Kazo

Methods and kits for treating oral mucositis are disclosed. The treatment comprises administering to a patient in need thereof a Reactive Oxygen Species scavenger in a pharmaceutically acceptable formulation.

Methods of treating oral mucositis

Assays for the detection of &bgr;-lactamase induction can be used to identify compounds that kill bacteria (i.e., bacteriocidal activity) or inhibit bacterial growth (i.e., bacteriostatic activity). The &bgr;-lactamase can be encoded, for example, by a &bgr;-lactamase gene carried by a bacterial host. The identified compounds can be use to treat bacterial infections in organisms such as mammals. The new methods can be used, for example, for high throughput screening of libraries of potential inhibitors.

Screening for antibiotics

Methods for treating cystic fibrosis in a mammal that include administering to the mammal an effective amount of a histatin, a histatin fragment, or a histatin-related peptide are disclosed.

Method for treating cystic fibrosis

Assays for the detection of .beta.-lactamase induction can be used to identify compounds that kill bacteria (i.e., bacteriocidal activity) or inhibit bacterial growth (i.e., bacteriostatic activity). The .beta.-lactamase can be encoded, for example, by a .beta.-lactamase gene carried by a bacterial host. The identified compounds can be use to treat bacterial infections in organisms such as mammals. The new methods can be used, for example, for high throughput screening of libraries of potential inhibitors.

The invention features two novel antibiotics, termed 15352A and 15352B, having the structures shown in the figures.

Growing community of inventors

Lexington, MA, United States of America

David M Rothstein